Cargando…
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. However, the proportion of breast cancers sensitive to anti-IL-6 therapies is not...
Autores principales: | Morancho, Beatriz, Zacarías-Fluck, Mariano, Esgueva, Antonio, Bernadó-Morales, Cristina, Cosimo, Serena Di, Prat, Aleix, Cortés, Javier, Arribas, Joaquín, Rubio, Isabel T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531/ https://www.ncbi.nlm.nih.gov/pubmed/27602583 http://dx.doi.org/10.18632/oncotarget.11815 |
Ejemplares similares
-
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015) -
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
por: Nadal-Serrano, Mercedes, et al.
Publicado: (2020) -
Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence
por: Morancho, Beatriz, et al.
Publicado: (2015) -
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2022) -
Gene expression‐based classifications of fibroadenomas and phyllodes tumours of the breast
por: Vidal, Maria, et al.
Publicado: (2015)